Boston Scientific Corporation BSX
45.13 USD +0.43 (+0.96%)
At closeNov 12, 2026, 7:33 AM EST
45.56 +0.43 +0.95%
Pre-market · Nov 12, 7:33 AM ET
43.87 Day range 45.82
39.57 52-week range 105.65
- YTD
- -52.67%
- 1 year
- -55.97%
News
marketbeat.com Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027 Boston Scientific NYSE: BSX executives said they expect durable growth across the company's interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face…
investorplace.com Insider Buying Signals: 3 Healthcare Stocks to Watch Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such…
zacks.com Wall Street Analysts Look Bullish on Boston Scientific (BSX): Should You Buy? Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
defenseworld.net Boston Scientific Corporation $BSX Stock Bought by Ethic Inc. Ethic Inc. boosted its position in Boston Scientific Corporation (NYSE: BSX) by 11.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange…
businesswire.com BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation's Directors and Officers for Breach of Fiduciary Duties – BSX NEW YORK--(BUSINESS WIRE)---- $BSX #NYSE--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE:…
zacks.com Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
benzinga.com Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.84% on an annualized basis producing an average annual return of 14.73%. Currently, Boston Scientific has a market…
benzinga.com TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46 TD Cowen analyst Joshua Jennings downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $56 to $46.
benzinga.com Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45 Barclays analyst Christopher Pasquale maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.- benzinga.com Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46 Jefferies analyst Matthew Taylor downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $60 to $46.
- benzinga.com Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48 Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $66 to $48.
benzinga.com RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52 RBC Capital analyst Kendall Au maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $70 to $52.- benzinga.com Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44 Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Neutral and lowers the price target from $48 to $44.
- benzinga.com Leerink Partners Maintains Outperform on Boston Scientific, Lowers Price Target to $50 Leerink Partners analyst Mike Kratky maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $55 to $50.
benzinga.com UBS Maintains Buy on Boston Scientific, Lowers Price Target to $57 UBS analyst Patrick Wood maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $67 to $57.
benzinga.com Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45 Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.
benzinga.com These Analysts Revise Their Forecasts On Boston Scientific After Q3 Results Boston Scientific beat Q3 estimates but cut FY26 guidance; Q4 forecasts missed expectations. Analysts adjusted price targets.
benzinga.com Baird Maintains Outperform on Boston Scientific, Raises Price Target to $51 Baird analyst David Rescott maintains Boston Scientific (NYSE:BSX) with a Outperform and raises the price target from $50 to $51.- benzinga.com BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $49 BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $56 to $49.
benzinga.com Needham Maintains Buy on Boston Scientific, Lowers Price Target to $48 Needham analyst Mike Matson maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $48.
benzinga.com Boston Scientific Overshadowed by Hackers, Headwinds, and Lower Guidance Boston Scientific slips after a cyber fallout offsets a Q3 consensus beat. Management targets a 2027 cycle trough and 2030 expansion.
benzinga.com Boston Scientific Q3 2026 Earnings Call Transcript Boston Scientific (NYSE:BSX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This content is powered by…- benzinga.com Boston Scientific Lowers FY2026 Adj EPS Guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 Est; Lowers FY2026 Sales Guidance from $21.178B-$21.379B to $20.927B vs $21.143B Est Boston Scientific (NYSE:BSX) lowers FY2026 Adj EPS guidance from $3.28-$3.32 to $3.16-$3.18 vs $3.23 analyst estimate. Lowers FY2026 sales outlook from $21.178 billion-$21.379 billion to $20.927…
benzinga.com Boston Scientific Sees Q4 Adj EPS $0.77-$0.79 vs $0.84 Est; Sees Sales $5.127B-$5.233B vs $5.404B Est Boston Scientific (NYSE:BSX) is looking for Q4 Adj EPS of $0.77-$0.79 vs $0.84 analyst estimate. sees sales of $5.127 billion-$5.233 billion vs $5.404 billion analyst estimate.- benzinga.com Boston Scientific Q3 Adj. EPS $0.73 Beats $0.72 Estimate, Sales $5.138B Beat $5.046B Estimate Boston Scientific (NYSE:BSX) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.72 by 1.39 percent. This is a 2.67 percent decrease over earnings of $0.75…
benzinga.com Microsoft, Alphabet On Deck Wednesday As AI Spending, Cloud Growth Face Test Microsoft and Alphabet headline Wednesday’s reports, with investors weighing whether AI infrastructure spending is translating into durable cloud and advertising growth. GE Vernova, Amphenol, Banco…- benzinga.com Stifel Maintains Buy on Boston Scientific, Lowers Price Target to $55 Stifel analyst Rick Wise maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $55.
- benzinga.com Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $51 Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $57 to $51.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Barclays Initiates Coverage On Boston Scientific with Equal-Weight Rating, Announces Price Target of $48 Barclays analyst Christopher Pasquale initiates coverage on Boston Scientific (NYSE:BSX) with a Equal-Weight rating and announces Price Target of $48.
benzinga.com Boston Scientific Appoints Joseph M. Fitzgerald As EVP And COO, Effective January 1, 2027 Fitzgerald currently serves as executive vice president and group president, Cardiovascular, Boston Scientific. Under his leadership, the company has strengthened its portfolio through organic…
benzinga.com If You Invested $1000 In Boston Scientific Stock 15 Years Ago, You Would Have This Much Today Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 14.35%. Currently, Boston Scientific has a market…- benzinga.com Elutia Obtains $8M Payment from Boston Scientific; Co. Now Fully Funded into 2029 Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced it has received the full $8 million held in escrow in connection with the sale…
benzinga.com FDA Flags Boston Scientific Catheter Recall Boston Scientific recalls Imager II Angiographic Catheters over tip detachment defect. Learn about patient risks & FDA safety updates.- benzinga.com Wells Fargo Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $48 Wells Fargo analyst Larry Biegelsen maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $50 to $48.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65 Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.
- benzinga.com Citigroup Downgrades Boston Scientific to Neutral, Lowers Price Target to $50 Citigroup analyst Joanne Wuensch downgrades Boston Scientific (NYSE:BSX) from Buy to Neutral and lowers the price target from $57 to $50.
benzinga.com Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.01% on an annualized basis producing an average annual return of 14.1%. Currently, Boston Scientific has a market…
benzinga.com Alpha Buying: 4 Falling Knives Insiders Are Buying There are dozens of reasons corporate executives sell shares. They may need money to pay taxes, buy a house, settle a divorce, diversify their wealth, or fund a new boat they will use three times…
benzinga.com Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.- benzinga.com BTIG Maintains Buy on Boston Scientific, Lowers Price Target to $56 BTIG analyst Marie Thibault maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $60 to $56.
benzinga.com Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack Boston Scientific expects a 2026 earnings miss after a cyberattack disrupted global operations. Manufacturing and shipping are recovering.- benzinga.com Boston Scientific Discloses Its Unlikely To Meet Its FY26 And Q3 Adj EPS And Net Sales Growth Guidance After Cybersecurity Incident Based on the information currently available as of the date of this Current Report on Form 8-K, the Company has determined that the incident is likely to have a material impact on the Company’s…
benzinga.com Boston Scientific Recalls Spinal Cord Stimulator Leads Over Fracture Risk Boston Scientific recalls Infinion CX SCS leads following 1,081 injury reports. Health authorities urge immediate return of unused inventory.
benzinga.com Boston Scientific Reports Global Disruption After Cybersecurity Incident Boston Scientific reports a cyber incident disrupting global operations, limiting system access and affecting order processing and shipments.
benzinga.com Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.- benzinga.com Boston Scientific Discloses Cybersecurity Threat Resulting In Disruption To Global Operations; Investigation Is Ongoing On August 25, 2026, Boston Scientific Corporation (the "Company") identified a cybersecurity incident affecting certain of its information technology systems that has resulted in a global disruption…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…